Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Arcus Biosciences Inc (RCUS)

Arcus Biosciences Inc (RCUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,588,039
  • Shares Outstanding, K 90,953
  • Annual Sales, $ 117,000 K
  • Annual Income, $ -307,000 K
  • 60-Month Beta 0.91
  • Price/Sales 13.64
  • Price/Cash Flow N/A
  • Price/Book 2.20
Trade RCUS with:

Options Overview Details

View History
  • Implied Volatility 89.64% ( +14.44%)
  • Historical Volatility 49.48%
  • IV Percentile 88%
  • IV Rank 52.69%
  • IV High 131.15% on 01/09/24
  • IV Low 43.41% on 05/08/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6,854
  • Volume Avg (30-Day) 971
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 9,469
  • Open Int (30-Day) 9,233

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -1.04
  • Number of Estimates 3
  • High Estimate -0.88
  • Low Estimate -1.26
  • Prior Year -1.04
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.10 +19.86%
on 04/19/24
18.07 -6.47%
on 05/15/24
+2.06 (+13.88%)
since 04/17/24
3-Month
14.10 +19.86%
on 04/19/24
20.31 -16.79%
on 02/27/24
+0.10 (+0.60%)
since 02/16/24
52-Week
12.95 +30.50%
on 11/13/23
25.47 -33.65%
on 08/23/23
-1.29 (-7.09%)
since 05/17/23

Most Recent Stories

More News
S&P Futures Tick Lower Ahead of FOMC Meeting, Microsoft and Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH24) are trending down -0.15% this morning as investors looked ahead to the first Federal Reserve monetary policy committee meeting of the year and quarterly reports from...

ESH24 : 5,101.67s (-1.01%)
SOFI : 7.28 (+2.25%)
ADM : 61.62 (+0.05%)
META : 471.91 (-0.28%)
IRBT : 10.84 (-3.26%)
MSFT : 420.21 (-0.19%)
GOOGL : 176.06 (+1.08%)
AMD : 164.47 (+1.14%)
PFE : 28.64 (-0.97%)
UPS : 149.24 (-0.28%)
SBUX : 77.85 (+3.41%)
DGE.LN : 2,800.500 (-0.59%)
From laggards to leaders: Small caps on the rise

Despite large-cap dominance, signs suggest a shift to small-cap leadership. Valuations, positive Q3 results, and historical patterns point to potential gains.

MDY : 551.69 (+0.11%)
TSLA : 177.46 (+1.50%)
XLC : 82.61 (+0.17%)
IWM : 208.08 (+0.07%)
RCL : 141.92 (-0.66%)
XLK : 211.82 (-0.22%)
NVDA : 924.79 (-1.99%)
META : 471.91 (-0.28%)
SPSM : 42.95 (-0.14%)
SPY : 529.45 (+0.14%)
VIR : 9.73 (-2.01%)
RCUS : 16.90 (-3.21%)
MarketBeat Week in Review – 7/10 - 7/14

As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week

ENPH : 114.32 (-2.17%)
ACCD : 7.48 (+2.05%)
PEP : 182.19 (-0.50%)
BYND : 7.19 (-0.14%)
ARKK : 45.45 (+1.09%)
PLTR : 21.76 (+0.51%)
BABA : 88.54 (+2.12%)
NVDA : 924.79 (-1.99%)
AVGO : 1,395.29 (-1.19%)
GILD : 67.72 (-0.21%)
ALVR : 0.7754 (+3.19%)
RCUS : 16.90 (-3.21%)
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.

GILD : 67.72 (-0.21%)
AMGN : 312.47 (-0.71%)
BMY : 44.03 (-0.18%)
NVS : 102.57 (-0.12%)
BGNE : 172.85 (+1.06%)
JSPR : 23.02 (+0.77%)
VIGL : 3.52 (-0.56%)
ALVR : 0.7754 (+3.19%)
RCUS : 16.90 (-3.21%)
FLACU : 9.50 (+2.48%)
3 Biotech Stocks to Buy for Long-Term Gains

The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors.

XBI : 91.18 (-1.52%)
CRSP : 56.22 (+0.99%)
NTLA : 26.22 (+0.19%)
CRBU : 3.39 (-5.57%)
REGN : 982.29 (+1.48%)
PFE : 28.64 (-0.97%)
VRTX : 445.21 (+1.04%)
GILD : 67.72 (-0.21%)
RCUS : 16.90 (-3.21%)
Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates

Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney disease.

RETA : 172.36 (+0.02%)
RCUS : 16.90 (-3.21%)
ALLO : 2.77 (-7.97%)
OCUP : 1.6850 (-2.88%)
TEVA Q1 Earnings Miss Estimates, Sales Beat, Stock Declines

TEVA reports mixed Q1 results, missing earnings estimates but beating the same for revenues. Stock falls.

TEVA : 16.29 (-0.06%)
RCUS : 16.90 (-3.21%)
ALLO : 2.77 (-7.97%)
OCUP : 1.6850 (-2.88%)
Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow

Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates. The company reiterates its 2023 guidance.

FOLD : 9.57 (+0.74%)
RCUS : 16.90 (-3.21%)
ALLO : 2.77 (-7.97%)
OCUP : 1.6850 (-2.88%)
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -2.83% and 4.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

RCUS : 16.90 (-3.21%)
FOLD : 9.57 (+0.74%)
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced...

RCUS : 16.90 (-3.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in...

See More

Key Turning Points

3rd Resistance Point 17.96
2nd Resistance Point 17.73
1st Resistance Point 17.32
Last Price 16.90
1st Support Level 16.68
2nd Support Level 16.45
3rd Support Level 16.04

See More

52-Week High 25.47
Fibonacci 61.8% 20.69
Fibonacci 50% 19.21
Fibonacci 38.2% 17.73
Last Price 16.90
52-Week Low 12.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar